Abiopharma

🔍 Shepard Alan K (Director)

Company: CNX Resources Corp (CNX)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 39,771 shares of Common shares, $0.01 par value per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 299,192.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 17,297 shares of Common shares, $0.01 par value per share at $35.38 per share (Direct)
  Date: 2026-08-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 281,895.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 39,771 shares of Performance Share Units (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2030-07-31 | equity_swap_involved: 0 | shares_owned_after: 287,501.00 | transaction_form_type: 4 | Footnotes: F4, F1, F4, F1, F5

Footnotes:

• F1: Represents the vesting of the first tranche of Performance Share Units ("PSUs") granted to the reporting person on August 1, 2023.
• F2: Represents shares automatically withheld to satisfy the reporting person's tax liability from the vesting of PSUs previously granted to him.
• F3: Of the shares owned directly, 86,856 are restricted stock units (including dividend equivalent rights).
• F4: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of common stock. The PSUs vest upon the common stock of CNX Resources achieving certain pre-determined prices per share in three tranches over approximately seven years.
• F5: The remaining PSUs have been further reduced by 56,062 target PSUs, which were not earned in the first tranche, and for which the reporting person has no further vesting opportunity.